Receptor Discordance and Molecular Subtype Changes in Visceral Metastases of Breast Cancer
Open Access
- 1 January 2026
- journal article
- research article
- Published by Taylor & Francis in Breast Cancer: Targets and Therapy
- Vol. ume 18, 1-14
Abstract
Background: Visceral metastases in breast cancer demonstrate considerable molecular heterogeneity. This study examines changes in receptor status and molecular subtypes between primary breast cancer and visceral metastases. Methods: A retrospective analysis was conducted on 430 patients diagnosed with breast cancer and visceral metastases, including 138 with lung metastases and 292 with liver metastases. Receptor statuses (estrogen receptor [ER], progesterone receptor [PR], human epidermal growth factor receptor 2 [HER2]) were assessed in both primary and metastatic tumors. Discordance in molecular subtypes was assessed, and factors influencing receptor changes were identified. Survival outcomes were estimated using Kaplan–Meier analysis. Results: Receptor discordance was observed in 47.9% (206/430) of patients, with a higher frequency in liver metastases (51.0%) than in lung metastases (41.3%). PR discordance was the most frequent (36.2%), followed by ER (18.9%) and HER2 (7.2%). Molecular subtype discordance occurred in 36.1% of patients, with the highest rate in Luminal A tumors (85.7%). Multivariate analysis identified pN3 stage and molecular subtype as independent predictors. Kaplan–Meier survival analysis showed that patients with ER gain had significantly improved disease-free survival (DFS) compared with those with ER loss (75.4 vs 44.5 months, P = 0.0092). Moreover, molecular subtype discordance was associated with longer DFS (63.9 vs 49.1 months, P = 0.0079). Conclusion: This study emphasizes that there are significant differences in receptor expression and molecular subtypes between primary breast tumors and their visceral metastases. The receptor is more likely to change in patients with liver metastasis and Luminal A or Luminal B (HER2+) tumors, highlighting the importance of repeat biopsy in the metastatic environment. These findings can be used to identify high-risk patients and provide them with better treatment plans.Keywords
This publication has 33 references indexed in Scilit:
- PTEN inactivating mutations are associated with hormone receptor loss during breast cancer recurrenceBreast Cancer Research and Treatment, 2025
- Receptor Discordance in Metastatic Breast Cancer; a review of clinical and genetic subtype alterations from primary to metastatic diseaseBreast Cancer Research and Treatment, 2024
- Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastasesEuropean Journal of Cancer, 2023
- Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastasesInternational Journal of Cancer, 2022
- Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysisBreast Cancer Research and Treatment, 2021
- Receptor discordance and phenotype change in metastatic breast cancerAsian Journal of Surgery, 2021
- Profile and outcome of receptor conversion in breast cancer metastases: a nation‐wide multicenter epidemiological studyInternational Journal of Cancer, 2020
- Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancerBreast Cancer Research and Treatment, 2020
- Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasisJournal of Neuro-Oncology, 2017
- Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours—a reviewCancer and Metastasis Reviews, 2016